1
|
Mena-Vázquez N, Fernández-Nebro A, Pego-Reigosa JM, Galindo M, Melissa-Anzola A, Uriarte-Isacelay E, Olivé-Marqués A, Aurrecoechea E, Freire M, Tomero E, García-Villanueva MJ, Stoye C, Salas-Heredia E, Bernal-Vidal JA, Salgado E, Blanco R, Javier Novoa F, Ibáñez-Barcelo M, Torrente-Segarra V, Narvaez J, Calvet J, Moriano Morales C, Ramon Vazquez-Rodriguez T, Garcia de la Peña P, Bohórquez C, Andreu-Sánchez JL, Cobo-Ibañez T, Bonilla G, Lozano-Rivas N, Montilla C, Toyos FJ, De la Fuente JLM, Expósito L, Ruiz-Lucea ME, Vals E, Manero-Ruiz J, Bernal-Vidal JA, Rua-Figueroa I. Hydroxychloroquine is associated with a lower risk of polyautoimmunity: data from the RELESSER Registry. Rheumatology (Oxford) 2021; 59:2043-2051. [PMID: 31808534 PMCID: PMC7382602 DOI: 10.1093/rheumatology/kez562] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/27/2019] [Revised: 10/18/2019] [Indexed: 12/18/2022] Open
Abstract
Objectives This article estimates the frequency of polyautoimmunity and associated factors in a large retrospective cohort of patients with SLE. Methods RELESSER (Spanish Society of Rheumatology Lupus Registry) is a nationwide multicentre, hospital-based registry of SLE patients. This is a cross-sectional study. The main variable was polyautoimmunity, which was defined as the co-occurrence of SLE and another autoimmune disease, such as autoimmune thyroiditis, RA, scleroderma, inflammatory myopathy and MCTD. We also recorded the presence of multiple autoimmune syndrome, secondary SS, secondary APS and a family history of autoimmune disease. Multiple logistic regression analysis was performed to investigate possible risk factors for polyautoimmunity. Results Of the 3679 patients who fulfilled the criteria for SLE, 502 (13.6%) had polyautoimmunity. The most frequent types were autoimmune thyroiditis (7.9%), other systemic autoimmune diseases (6.2%), secondary SS (14.1%) and secondary APS (13.7%). Multiple autoimmune syndrome accounted for 10.2% of all cases of polyautoimmunity. A family history was recorded in 11.8%. According to the multivariate analysis, the factors associated with polyautoimmunity were female sex [odds ratio (95% CI), 1.72 (1.07, 2.72)], RP [1.63 (1.29, 2.05)], interstitial lung disease [3.35 (1.84, 6.01)], Jaccoud arthropathy [1.92 (1.40, 2.63)], anti-Ro/SSA and/or anti-La/SSB autoantibodies [2.03 (1.55, 2.67)], anti-RNP antibodies [1.48 (1.16, 1.90)], MTX [1.67 (1.26, 2.18)] and antimalarial drugs [0.50 (0.38, 0.67)]. Conclusion Patients with SLE frequently present polyautoimmunity. We observed clinical and analytical characteristics associated with polyautoimmunity. Our finding that antimalarial drugs protected against polyautoimmunity should be verified in future studies.
Collapse
Affiliation(s)
- Natalia Mena-Vázquez
- Instituto de Investigación Biomédica de Málaga - IBIMA, Malaga.,UGC de Reumatología, Hospital Regional Universitario de Málaga, Málaga
| | - Antonio Fernández-Nebro
- Instituto de Investigación Biomédica de Málaga - IBIMA, Malaga.,UGC de Reumatología, Hospital Regional Universitario de Málaga, Málaga.,Departamento de Medicina, Universidad de Málaga, Málaga
| | | | - María Galindo
- Departamento de Reumatología, Hospital Universitario 12 de Octubre, Madrid
| | - Ana Melissa-Anzola
- Departamento de Reumatología, Hospital General Universitario Gregorio Marañón, Madrid
| | | | - Alejandro Olivé-Marqués
- Departamento de Reumatología, Hospital Universitari Germans Trias i Pujol, Badalona, Catalunya
| | - Elena Aurrecoechea
- Departamento de Reumatología, Hospital Sierrallana, Torrelavega, Cantabria
| | - Mercedes Freire
- Departamento de Reumatología, Hospital Juan Canalejo de La Coruña, A Coruna, Galicia
| | - Eva Tomero
- Instituto de Investigación Biomédica de Málaga - IBIMA, Malaga
| | | | - Claudia Stoye
- Departamento de Reumatología, Hospital de Navarra, Pamplona, Navarra
| | | | | | - Eva Salgado
- Departamento de Reumatología, Complejo Hospitalario de Orense, Ourense, Galicia
| | - Ricardo Blanco
- Departamento de Reumatología, Hospital Universitario Marques de Valdecilla, Santander, Cantabria
| | - Francisco Javier Novoa
- Departamento de Reumatología, Hospital Universitario de Gran Canaria Dr Negrin, Las Palmas de Gran Canaria
| | - Mónica Ibáñez-Barcelo
- Departamento de Reumatología, Hospital Son Llatzer, Palma de Mallorca, Illes Balears
| | | | - Javier Narvaez
- Department of Rheumatology L'Hospitalet de Llobregat, Hospital Universitari de Bellvitge, Barcelona
| | - Joan Calvet
- Departamento de Reumatología, Consorci Corporació Sanitària Parc Taulí, Sabadell, Catalunya
| | | | | | | | - Cristina Bohórquez
- Departamento de Reumatología, Hospital Universitario Principe de Asturias, Alcala de Henares, Madrid
| | - José Luis Andreu-Sánchez
- Departamento de Reumatología, Hospital Universitario Puerta del Hierro Majadahonda, Majadahonda, Madrid
| | - Tatiana Cobo-Ibañez
- Departamento de Reumatología, Hospital Universitario Infanta Sofia, San Sebastian de los Reyes, Madrid
| | - Gema Bonilla
- Departamento de Reumatología, Hospital Universitario La Paz, Madrid
| | - Nuria Lozano-Rivas
- Departamento de Reumatología, Hospital Clínico Universitario Virgen de la Arrixaca, Murcia
| | - Carlos Montilla
- Departamento de Reumatología, Hospital Clínico de Salamanca, Salamanca, Castilla y León
| | - Francisco Javier Toyos
- Departamento de Reumatología, Hospital Universitario Virgen Macarena, Sevilla, Andalucía
| | | | - Lorena Expósito
- Departamento de Reumatología, Hospital Universitario de Canarias, La Laguna, Canarias
| | | | - Elia Vals
- ReumatologíaValencia, Hospital Universitario Dr Peset, Comunitat Valenciana
| | | | - Jose A Bernal-Vidal
- Reumatología, Hospital General Universitario de Alicante, Valencia, Alicante
| | - Iñigo Rua-Figueroa
- Reumatología, Hospital Universitario de Gran Canaria Dr Negrin, Las Palmas de Gran Canaria, Spain
| |
Collapse
|
2
|
Rosas J, Llinares-Tello F, Senabre-Gallego JM, Barber-Vallés X, Santos-Soler G, Salas-Heredia E, Pons Bas A, Cano Pérez C, García-Carrasco M. Obesity decreases clinical efficacy and levels of adalimumab in patients with ankylosing spondylitis. Clin Exp Rheumatol 2017; 35:145-148. [PMID: 27908311] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/13/2016] [Accepted: 09/02/2016] [Indexed: 06/06/2023]
Abstract
OBJECTIVES Obesity can be a factor that affects response to anti-TNF drugs. However, studies on patients with ankylosing spondylitis (AS) are rare. We aimed to determine whether obesity affects serum levels of adalimumab (ADL), and immunogenicity and clinical efficacy of the drug in patients with AS. METHODS A cross-sectional study on 57 patients with axial AS receiving ADL was conducted. They received DMARD per standard of care at their rheumatologist's discretion. Patients' body mass index (BMI) was obtained when ADL treatment began. Clinical response was evaluated using the Spanish versions of the BASDAI index and the ASDAS ESR index. Serum concentrations of free ADL (trough level) and anti-ADL antibodies were measured using Promonitor-ADL and Promonitor Anti-ADL ELISA kits (Progenika Grifols SA, Spain), just prior to the next subcutaneous injection of ADL. RESULTS Patients with BMI >30 kg/ m2 (obese) as opposed to BMI <25 kg/ m2 (normal), presented lower blood ADL levels [5.0 (5.52) vs. 9.14 (4.3), p=0.032], increased ASDAS scores (2.58 [0.79] vs. 1.9 [0.83], p=0.03), and shorter ADL treatment time: 1.01 [0.84] vs. (1.85 [1.65]; p=0.08]), and increased BASDAI results (5.04 [2.5] vs. 3.5 [1.88]; p=0.06). Obese patients showed a lower probability of clinical response to ADL versus non-obese patients with regard to achieving BASDAI ≤4 (OR: 3.5, 95%CI: 0.84-17.19; p=0.05) or ASDAS ≤2.1 (OR: 4.64, 95%CI: 1.02-24.13; p=0.02). CONCLUSIONS Of the AS patients receiving treatment with ADL, those that are obese had significantly lower serum ADL levels and decreased clinical response without an increase in immunogenicity.
Collapse
Affiliation(s)
- José Rosas
- Rheumatology Department, Marina Baixa Hospital, Villajoyosa, Alicante, Spain.
| | | | | | | | | | | | - Ana Pons Bas
- Rheumatology Department, Marina Baixa Hospital, Villajoyosa, Alicante, Spain
| | - Catalina Cano Pérez
- Rheumatology Department, Marina Baixa Hospital, Villajoyosa, Alicante, Spain
| | - Mario García-Carrasco
- Systemic Autoimmune Disease Research Unit HGR-36-CIBIOR IMSS Puebla; and Department of Rheumatology and Immunology, Benemérita Universidad Autónoma of Puebla, México
| |
Collapse
|
6
|
Rosas J, Llinares-Tello F, de la Torre I, Santos-Ramírez C, Senabre-Gallego JM, Valor L, Barber-Vallés X, Hernández-Flórez D, Santos-Soler G, Salas-Heredia E, Carreño L. Clinical relevance of monitoring serum levels of adalimumab in patients with rheumatoid arthritis in daily practice. Clin Exp Rheumatol 2014; 32:942-948. [PMID: 25327159] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/09/2014] [Accepted: 06/24/2014] [Indexed: 06/04/2023]
Abstract
OBJECTIVES The aim of this paper is to assess the usefulness of measuring serum levels of adalimumab (ADL) and anti-ADL antibodies in 57 patients with rheumatoid arthritis (RA) treated with ADL for at least 3 months in daily practice. METHODS All patients received concomitant disease-modifying anti-rheumatic drug (DMARD). Receiver-operator characteristics (ROC) analysis was used to obtain the cut-off value of ADL for low disease activity (DAS28-ESR ≤3.2). RESULTS Anti-ADL antibodies were detected in 4 (7%) patients with a mean (SD) DAS28 score of 4.6 (0.9). Patients with positive anti-ADL antibodies had significantly lower levels of ADL and higher DAS28 scores than those with negative antibodies. Patients with DAS28 ≤3.2 as compared with patients with DAS28 >3.2 showed significantly better SDAI score, higher serum concentrations of ADL and none of them showed anti-ADL antibodies. The cut-off of serum level of ADL for DAS28 <3.2 was 4.3 mg/L. According to serum levels of ADL, patients were grouped into group 1 (low level) <5.5 mg/L, group 2 (medium level) 5.5-11.3 mg/L and group 3 (high level) >11.3 mg/L. Patients in the medium group were closed to clinical remission (median DAS28 2.7) and patients in the high group were on clinical remission (DAS28 2.1). CONCLUSIONS Serum levels of ADL should be maintained >4.3 mg/L. In patients with ADL levels >11.3 mg/L, a decrease of the dose of ADL or an increase in the interval between doses may be planned. The presence of anti-ADL antibodies was associated with a loss of clinical efficacy of ADL.
Collapse
MESH Headings
- Adalimumab
- Aged
- Antibodies, Monoclonal, Humanized/administration & dosage
- Antibodies, Monoclonal, Humanized/blood
- Antibodies, Monoclonal, Humanized/immunology
- Antirheumatic Agents/administration & dosage
- Antirheumatic Agents/blood
- Antirheumatic Agents/immunology
- Area Under Curve
- Arthritis, Rheumatoid/blood
- Arthritis, Rheumatoid/diagnosis
- Arthritis, Rheumatoid/drug therapy
- Arthritis, Rheumatoid/immunology
- Biomarkers/blood
- Cross-Sectional Studies
- Drug Monitoring
- Female
- Humans
- Male
- Middle Aged
- Predictive Value of Tests
- ROC Curve
- Spain
- Time Factors
- Treatment Outcome
Collapse
Affiliation(s)
- José Rosas
- Department of Rheumatology, Marina Baixa Hospital, Villajoyosa, Alicante, Spain.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
7
|
Senabre-Gallego JM, Santos-Ramírez C, Santos-Soler G, Salas-Heredia E, Sánchez-Barrioluengo M, Barber X, Rosas J. Long-term safety and efficacy of etanercept in the treatment of ankylosing spondylitis. Patient Prefer Adherence 2013; 7:961-72. [PMID: 24101863 PMCID: PMC3790868 DOI: 10.2147/ppa.s33109] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/21/2022] Open
Abstract
To date, anti-tumor necrosis factor alfa (anti-TNF-α) therapy is the only alternative to nonsteroidal anti-inflammatory drugs for the treatment of ankylosing spondylitis. Etanercept is a soluble TNF receptor, with a mode of action and pharmacokinetics different to those of antibodies and distinctive efficacy and safety. Etanercept has demonstrated efficacy in the treatment of ankylosing spondylitis, with or without radiographic sacroiliitis, and other manifestations of the disease, including peripheral arthritis, enthesitis, and psoriasis. Etanercept is not efficacious in inflammatory bowel disease, and its efficacy in the treatment of uveitis appears to be lower than that of other anti-TNF drugs. Studies of etanercept confirmed regression of bone edema on magnetic resonance imaging of the spine and sacroiliac joint, but failed to reduce radiographic progression, as do the other anti-TNF drugs. It seems that a proportion of patients remain in disease remission when the etanercept dose is reduced or administration intervals are extended. Etanercept is generally well tolerated with an acceptable safety profile in the treatment of ankylosing spondylitis. The most common adverse effect of etanercept treatment is injection site reactions, which are generally self-limiting. Reactivation of tuberculosis, reactivation of hepatitis B virus infection, congestive heart failure, demyelinating neurologic disorders, hematologic disorders like aplastic anemia and pancytopenia, vasculitis, immunogenicity, and exacerbation or induction of psoriasis are class effects of all the anti-TNF drugs, and have been seen in patients with ankylosing spondylitis. However, etanercept is less likely to induce reactivation of tuberculosis than the other anti-TNF drugs and it has been suggested that etanercept might be less immunogenic, especially in ankylosing spondylitis. Acute uveitis, Crohn's disease, and sarcoidosis are other adverse events that have been rarely associated with etanercept therapy in patients with ankylosing spondylitis.
Collapse
Affiliation(s)
| | | | | | | | - Mabel Sánchez-Barrioluengo
- INGENIO (Instituto de Gestión de la Inovación y del Conocimiento) (CSIC [Consejo Superior de Investigaciones Científicas]-UPV [Universidad Politécnica de Valencia]), Universitat Politècnica de València, Valencia, Spain
| | - Xavier Barber
- CIO (Centro de Investigación Operativa)-UMH (Universidad Miguel Hernández), Universidad Miguel Henández, Elche, Spain
| | - José Rosas
- Rheumatology, Hospital Marina Baixa, Villajoyosa, Spain
| | | |
Collapse
|
10
|
Senabre-Gallego JM, Rosas-Gómez de Salazar J, Santos-Soler G, Santos-Ramírez C, Sánchez-Barrioluengo M, Salas-Heredia E, Barber-Vallés X, Cano-Pérez C, Llahí-Vidal N, Riestra-Juán R. [Duration of treatment with etanercept and motives for discontinuation in a cohort of patients with rheumatic disease]. ACTA ACUST UNITED AC 2011; 7:385-8. [PMID: 22078696 DOI: 10.1016/j.reuma.2011.06.005] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/17/2011] [Revised: 06/17/2011] [Accepted: 06/28/2011] [Indexed: 11/15/2022]
Abstract
OBJECTIVE To evaluate the duration of etanercept (ETN) treatment and motives for discontinuation in our local cohort of patients with rheumatic pathology and compare them to the group with other biological treatments. PATIENTS AND METHODS Prospective observational cohort study. Disease diagnosis, start and end date and motive for discontinuation were recorded. Survival estimation was explored using Kaplan-Meier analysis with remaining patients censored at 1-year, 2-years and 5-years follow-up. RESULTS Ninety-two (45%) out of 205 patients started ETN treatment. Disease diagnoses recorded were: 48% rheumatoid arthritis, 33% ankylosing spondylitis, 11% psoriatic arthritis, 8% others (juvenile idiopathic arthritis, inflammatory bowel disease related spondylitis, SAPHO syndrome). 52% of patients are still on the drug. The motives for discontinuation were: inefficacy (65%), adverse events (33%) and lack of compliance (2%). Two patients discontinued ETN due to prolonged disease control. Adverse events were: infection (4 patients), post-injection skin reaction (3), uveitis (3), neoplasia (2) and others (3). Using a Kaplan-Meier analysis, at 1-year 64% (CI(95%) 54-74) of patients with ETN treatment had not experienced treatment failure, at 2-years, 59% (48-69) and at 5-years, 43% (30-52). With the rest of biologicals estimated survival was 61% (51-68), 47,5% (40-55) and 23% (10,5-32) respectively. Statistical analysis revealed significant differences (log-rank: P=.024; Breslow: P=.068; Tarone-Ware: P=.040). CONCLUSIONS In our cohort of patients treated with ETN the estimated survival was better than patients treated with other biological drugs at 1-year, 2-years and 5-years.
Collapse
|